1097920-64-3 Usage
Uses
Used in Pharmaceutical Industry:
1-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential biological activities. Its unique structure allows for the development of new drugs with specific therapeutic targets.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone is utilized as a precursor in the creation of agrochemicals, leveraging its chemical properties to enhance crop protection and management.
Further research and studies are essential to fully explore the potential applications and properties of 1-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone, expanding its use across various industries and scientific fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1097920-64-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,7,9,2 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1097920-64:
(9*1)+(8*0)+(7*9)+(6*7)+(5*9)+(4*2)+(3*0)+(2*6)+(1*4)=183
183 % 10 = 3
So 1097920-64-3 is a valid CAS Registry Number.
1097920-64-3Relevant academic research and scientific papers
DI(ARYLAMINO)ARYL COMPOUND
-
Page/Page column 37, (2010/04/25)
The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.
